Drug intelligence / Profile preview

verducatib

Development stage: Phase 3
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

Verducatib is a novel, oral small molecule inhibitor of dipeptidyl peptidase 1 (DPP1), also known as cathepsin C (CatC)[1][3][5][9]. By targeting DPP1/CatC, verducatib reduces the activation of neutrophil serine proteases, which are implicated in airway inflammation and tissue damage in bronchiectasis. Its mechanism aims to decrease airway inflammation and the frequency of exacerbations in patients with bronchiectasis. Verducatib was developed as a new molecular entity and received FDA breakthrough therapy designation in 2024 for bronchiectasis[5].

Brand names: verducatib
Other names: BI 1291583BI1291583BI-1291583

Targets

CTSC (DPP1)

Beyond the preview

Go deeper on verducatib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on verducatib.

Explore the full profile